Clinical Trials Browser

Phase 1/2 × urelumab × Lymphoid × Clear all

NCT02253992 2020-10-05

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

232 enrolled 17 charts

LymphoidOther solid neoplasm

Advanced Solid Tumors